- This event has passed.
New UROwebinar: “Imaging and PSA assessment in nmCRPC patients and the treatment consequences” on 15 June 2021 @ 18h30 – 19h30.
15 Jun @ 6:30 pm - 7:30 pm
Dear SAUA Memeber,
Join us in the latest online educational event by the European School of Urology (ESU): the UROwebinar “Imaging and PSA assessment in nmCRPC patients and the treatment consequences”.
This UROwebinar will be presented by renowned experts in the field from the European School of Urology (ESU). The UROwebinar is free to attend.
[Pictured from left to right]
Moderator: Dr. J. Walz (FR)
Presenters: Prof. T. Steuber (DE), and Prof. B. Tombal (BE)
Save the date: Tuesday, 15 June 2021
Time: 18:30 – 19:30
Three pivotal trials, PROSPER, SPARTAN and ARAMIS, have shown improved cancer control when treating patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and low prostate-specific antigen (PSA) doubling time.
The definition of the non-metastatic stage is much depending on the sensitivity of the imaging test, rendering the non-metastatic stage as selection criteria weak. In this context, PSA gains a major role as selection criteria for treatment. On the other hand, in CRPC, PSA has limitations in treatment monitoring and imaging might be a more reliable tool to decide when treatment needs to be changed.
This webinar sheds light into the difficulties encountered with PSA and imaging when treating nmCRPC patients.
Collect your CME credit
You will receive 1 European CME credit (ECMEC®) when you complete the questionnaire provided at the end of this webinar.
How to join the UROwebinar
|This activity is supported by an educational grant with no involvement in the programme nor speakers.|
If you are interested in our other UROwebinars (live or on demand), keep an eye on this overview. Update your MyEAU preferences to include your topics of interest. You will only receive e-mails about UROwebinars on your preferred topic(s).